Professional Documents
Culture Documents
NanoAdvil
NanoAdvil
Nano Advil LLc. has the capability to use our own proprietary nano-technology
platform to make an inventory of nano-technology based consumer products that will
provide any Pharmaceutical company with a major advantage in the market place. In
addition, we are looking to partner with an established Pharmaceutical company to
propose solutions and create a suite of patented OTC and Rx products in line with
our nano-technology competency and expertise.
Principals
Dr. Mewa Singh
Dr. Mewa Singh has 18 years of experience in product development in the field of
biotechnology. He is currently working on a process for discovery of new nano-medicines in
various therapeutic areas. Dr. Mewa is specialized in various fields including new labs setup,
manufacture of biopharmaceuticals and project management / leadership associated with
product development. He has already delivered 23 products in the biopharmaceutical market
including a nano-medicine for arthritis, Neisseria meningitides vaccine, and a compound
formulated to treat acid reflux.
WHO Report
The poor dissolution and/or permeability of these drugs often result in low and
highly variable bioavailability.
What is new
It will provide more than a nano-medicine
Ibuprofen (advil etc.) is one of the most commonly used pain relievers due to its
effectiveness and high tolerability in doses of 200 mg and 400 mg. Based on the
amounts of ibuprofen produced globally, a consumption of around 30 billion tablets
per year can be assumed. The available dosage forms mostly contain ibuprofen in
the acid form in view of the lower costs . Ibuprofen, however, has a poor and highly
pH-dependent solubility. As the solubility increases above a pH of 6.5, the active
ingredient is dissolved and absorbed only in the intestinal tract but not in the
stomach. Depending on the pH conditions in the intestinal tract, absorption may be
further delayed due to physiological reasons. This is confirmed by numerous blood
level tests which show a maximum blood level 1.5 to 2 hours after ingestion. This
delay is a great disadvantage because patients expect a fast onset of the analgesic
effect when taking a pain reliever and tend to unnecessarily raise the dosage when
the effect is delayed.
A clear improvement was, however, achieved through the use of ibuprofen salts
with good water solubility such as ibuprofen lysinate, ibuprofen arginate and
ibuprofen sodium salt. The distinct acceleration of absorption is astounding, since
the ibuprofen salts are usually released under acidic conditions in the stomach
which leads to precipitation of ibuprofen.
Nano Ibuprofen
Tons of Raw Material
Ready to Formulate
Advil
NanoVil
Advil
NanoAdil
Advil
Nanovil
After 1 minute
After 15
minute
After 5 minute
After 10
minute
After 30
minute
NanoVil solubility after One minute Advil solubility after One minute
Solubility
NanoVil
Advil
Advil
NanoAdvil
NanoVil
Ibuprofen
In pH2.3
NanoVil
Solubility in water
1.4
5mg/ml
1.2
1
2.5
1.25mg/ml
0.8
1.5
0.4
Axis Title
0.64mg/ml
0.32mg/ml
0.2
1
0.5
0
10
30
Time
20
2.5mg/ml
So What ?!
One Player : Us
Hybrid Nanoengineering
Hybrid Nanoengineerin
Conclusion
Preliminary in vitro data show that NanoVil is a
superior fast release, improved NSAID formulation
of Ibuprofen compared with some brands.
We suggest joint collaboration with GAP, LLC to
proceed with in-vitro and in-vivo trials with NanoVil.
Furthermore, we suggest joint collaboration to
allow us to introduce the platform of our
technology to explore further opportunities for use
of fast release improved bioavailability technology
with other OTC/Rx drugs in your portfolio.
What next
Needed a partner for product development
through bioequivalent and FDA approvals.
Needed a strong marketing partner.
Proposal:
Joint Development Program
Nano science and technology are advancing quickly; therefore, the status of nano
technology commercialization is rapidly changing. Meda Biotech LLC believes
that a successful development program using this technology is possible, but it
will require an open and honest collaborative relationship with a partner and with a
clear understanding of the goals.
We are looking forward to a joint development program with a major partner that
will bring ideas, compatibility, aligned interests, complementary experience and
skills. The ideal partner would be an industry leader who will give us the
opportunity to apply our novel nanotechnology to provide innovative new products
to consumers and patients.
You can contact us to discuss ways to work together to pursue current and/or
future development opportunities using our new nanotechnology.
Questions?
Please contact Mewa Singh PhD via:
mewasinghsandhu@hotmail.com
www.nanomeda.com
Tele#: 609-902-7128
Meda Biotech